Related Experiment Video
Updated: Dec 23, 2025

04:49
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
Published on: December 12, 2019
9.6K
Developing a Batch Isolation Procedure and Running It in an Automated Semicontinuous Unit: AWL CFD25 Case Study
Sara Ottoboni1, Muhid Shahid1, Christopher Steven1,2
1EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde, Glasgow G1 1RD, U.K.
Summary
Developing a scalable drug isolation strategy is streamlined with the CFD25 device. This versatile tool enables batch process optimization and semicontinuous manufacturing using the same parameters, reducing R&D costs and time.
Area of Science:
- Chemical Engineering
- Pharmaceutical Manufacturing
- Process Development
Background:
- Transitioning from laboratory to continuous manufacturing presents challenges in developing adaptable process strategies.
- Current industrial practice involves batch optimization followed by parameter transfer, often requiring extensive re-evaluation for different equipment or mechanisms, increasing costs and time.
- The need for a unified approach to optimize isolation in batch and scale to continuous or semicontinuous processes is critical.
Purpose of the Study:
- To evaluate the CFD25 device as a tool for developing and transferring isolation strategies from batch to semicontinuous pharmaceutical manufacturing.
- To investigate the impact of input slurry properties (solid loading, particle size, solvent) on filtration and product characteristics.
- To assess the consistency and comparability of isolated product properties between batch development and semicontinuous production.
Main Methods:
- Utilized a d-optimal screening design of experiments (DoE) to optimize batch isolation conditions using the CFD25 device.
- Investigated various crystallization and wash solvents, including impurities, to mimic real-world isolation scenarios.
- Transferred the optimized batch strategy to a semicontinuous run on the same CFD25 equipment, measuring key performance indicators like throughput, cake resistance, purity, and residual solvent content.
Main Results:
- The CFD25 successfully enabled both batch optimization and semicontinuous production using identical process parameters without equipment modification.
- Isolated product properties from the semicontinuous run were generally comparable to those developed in batch, validating the transferability of the DoE-derived strategy.
- Minor variations in residual solvent content were observed in semicontinuous runs, attributed to filter plate blockage, but overall mean properties remained consistent.
Conclusions:
- The CFD25 is a versatile tool for developing new chemical entity isolation strategies in batch and scaling directly to semicontinuous active pharmaceutical ingredient production.
- The DoE approach effectively predicted and guided the isolation strategy, demonstrating successful transferability to a semicontinuous process.
- This integrated approach significantly reduces R&D costs, time, and material consumption associated with process scale-up.

